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In this perspective we consider new aspects of ligand-induced estrogen receptor α (ERα) degradation.What
are the possible roles of CSN5/Jab1 and the CSN complex in this process? We compare hormone (estrogen)
or pure antagonist (fulvestrant) induced degradation of ERα and review the effects of kinase-inhibitors and
CRM1-dependent nuclear export on ERα degradation and transcription activation. A model for ERα action
integrating these new actors is proposed and the relation between hormone-induced ERα degradation and
transcription-activation is discussed.
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Introduction
Over the last few years, the involvement of the
proteasome pathway in ligand-dependent nuclear receptor
degradation has been established.This pathway entails
first a polyubiquitination of the substrate, catalyzed by
three factors (E1, E2 and E3), followed by its proteolysis
by the proteasome. Recently, the role of the CSN complex
that regulates the activity of a class of E3 ubiquitin ligases,
the cullin RING ubiquitin ligase superfamily, was
demonstrated.The cullin subunits of these ubiquitin
ligases are modified by the conjugation of an ubiquitin-like
protein, NEDD8.The neddylated subunit Cul1 is
selectively degraded. Recent data demonstrate that CSN,
via its subunit CSN5/Jab1, dennedylates cullin, thus
increasing the activity of the E3 ligases [Wee et al., 2005].
Several lines of evidence suggest that CSN is involved
in ligand-dependant nuclear receptor degradation. First,
estrogen receptor α (ERα) degradation is dependant on
the neddylation pathway [Fan et al., 2003]; second,
CSN5/Jab1 interacts with both the progesterone receptor
and the coactivator SRC1 and is itself a coactivator of
the nuclear receptors [Fan et al., 2003]; third, Jab1/CSN5
increases hormone-induced ERα degradation [Fan et al.,
2003].
The nature of the ligand affects ERα degradation
differently: estradiol and the pure antagonist fulvestrant
induce ERα degradation by the proteasome, whereas
the mixed antagonist tamoxifen stabilizes Erα
[Wijayaratne and McDonnell, 2001].Thus, degradation
may play an important role in ERα function and/or the
action of its antagonists. ERα undergoes post translational
modifications such as phosphorylation [Lannigan, 2003],
acetylation [Wang et al., 2001] or sumoylation [Sentis et
al., 2005]. However, the role of such modifications in
targeting ERα for degradation remains unclear. A kinase
activity, inhibited by curcumin, is associated to CSN. At
least two curcumin-sensitive kinases, CKII and PKD,
which co-purify with CSN, could contribute to this activity
[Uhle et al., 2003]. CKII phosphorylates ERα on Ser167
in response to estradiol [Lannigan, 2003].The inhibition
of ERα degradation by curcumin and the
co-immunoprecipitation of Jab1/CSN5 with ERα in the
presence of curcumin, suggest that this kinase activity
could participate in targeting ERα for degradation. In
addition, the inhibition by curcumin of the interaction of
ERα with its DNA target, points towards a role of this
complex in transcription activation [Callige et al., 2005].
The discovery that E2 and E3 factors and proteasome
subunits associate with the transcriptional machinery,
reinforces the hypothesis that the degradation of nuclear
receptors could be linked to transcriptional activation and
may be necessary for efficient transcriptional activity
[Nawaz and O'Malley, 2004]. Here we discuss ERα
degradation pathways in the presence of different ligands
and the role of this degradation in ERα function.
Which E3 ligases are involved in ERα
degradation?
The demonstration that the NEDD8 pathway is required
for proteasome mediated degradation of ERα, suggests
that the E3 ligases involved belong to the cullin RING
ubiquitin ligase superfamily.Within this family, MDM2
and E6-AP, were identified as ERα coactivators [Nawaz
et al., 1999; Saji et al., 2001]. MDM2 is also involved in
the degradation of glucocorticoid and androgen receptors
[Kinyamu and Archer, 2003; Lin et al., 2002] and thus is
a good candidate for ERα polyubiquitination. ERα could
also be a substrate for BRCA1/BARD1, another potential
E3 ligase, which is recruited by Phospho-Pol II and is
involved in the degradation of both chromatin proteins
and active RNA polymerase II [Starita and Parvin, 2003].
One could speculate its involvement in ERα degradation
since this degradation is concomitant with transcriptional
activation. However BRCA1/BARD1 belongs to the HECT
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pathway regulates its activity.
What role do coactivators and adaptors
play in ERα degradation?
Transcription activation by ERα involves a number of
co-regulators, in particular coactivators of the p160 family
(SRC1/SRC2/SRC3).The activity of SRC3 (the major
ERα coactivator in breast cancer cell lines) is regulated
by phosphorylation [Wu et al., 2004]. Hormone-induced
transcription requires the dissociation of a corepressor
(N-CoR/SMRT) from ERα and its replacement by a
coactivator from the p160 family.TBLR1, a protein that
shares homology with TBL1 (Transducinβ-like1),
selectively mediates corepressor/coactivator exchange
upon ligand binding to nuclear receptors [Perissi et al.,
2004].
Several observations converge towards a link between
the recruitment of ERα cofactors and ligand-dependent
degradation by the proteasome. Suppression of
SRC3/AIB1 by siRNA leads to ERα stabilization in
presence of estradiol [Shao et al., 2004] and SRC3/AIB1
itself is degraded by the proteasome in a
hormone-dependent process [Perissi et al., 2004],
suggesting a role for SRC3/AIB1 in ERα degradation.
Nuclear receptor co-factors such as TBL1 and TBLR1
(originally identified as components of an N-CoR
complex), besides their ERα-cofactor exchange activity,
serve as specific adaptors for the recruitment of the
conjugating/19S proteasome complex and thus participate
in co-factor dynamics at the promoter during the
transcription initiation process [Perissi et al., 2004].
In which cellular compartment is ERα
degraded?
Inhibition of CRM1-dependent nuclear export by
leptomycin B blocks estrogen-dependent, but not
fulvestrant-induced degradation of ERα.This
demonstrates that the two ligands induce ERα
degradation through different pathways, taking place in
different cellular compartments. In the presence of
estradiol ERα is degraded by a cytoplasmic fraction of
the proteasome, whereas in the presence of fulvestrant
it is degraded in the nucleus [Callige et al., 2005].These
findings reinforce observations demonstrating rapid
sequestration of the ERα-fulvestrant complex in a
salt-insoluble, nuclear compartment [Giamarchi et al.,
2002] and reduced mobility of the ERα-fulvestrant
complex relative to the estradiol-ERα complex in the
nucleus [Stenoien et al., 2001].The fact that fulvestrant
is unable to promote either chromatin remodeling over
the TFF1 estrogen-regulated promoter [Giamarchi et al.,
2002], or binding of ERα to its DNA target within the same
promoter [Reid et al., 2003], indicates that the nuclear
sub-compartment in which the fulvestrant-ERα complex
is degraded, must be distinct from the sub-compartment
in which transcription takes place.The nature of the
nuclear compartment in which this degradation takes
place remains unknown.To understand better the
mechanism of action of the pure antiestrogen fulvestrant,
several issues need to be elucidated:What is the nature
of the compartment in which ERα is sequestered? Does
fulvestrant play a direct role in such targeting, e.g., by
directly recruiting a cofactor that changes the fate of
ERα-fulvestrant complex? Do corepressors or
coactivators play a role in this process (as suggested by
the fact that suppression of SRC3/AIB1 by siRNA leads
to ERα stabilization in presence of estradiol but not of
fulvestrant) [Shao et al., 2004]?
What is the link between ERα
degradation and estradiol induced
transcription?
The pathways involved in ERα degradation differ,
depending on the ligand (hormone or full antagonist, such
as fulvestrant). A phosphorylation event catalysed by a
curcumin-sensitive kinase, that could be CKII, is
necessary for both estradiol- and fulvestrant-induced ERα
degradation [Callige et al., 2005], making it unlikely that
this phosphorylation plays a role in the targeting of ERα
to different degradation-compartments.The exact role of
SRC3/AIB1 in each step of the hormone-induced ERα
degradation process remains to be determined.The fact
that ERα-OH-tamoxifen complex (that cannot recruit
coactivators) is not released from target promoters
[Wijayaratne and McDonnell, 2001], along with the
observations that SRC3 is co-degraded with ERα [Shao
et al., 2004] and that suppression of SRC3 expression
abrogates ERα degradation [Lonard et al., 2000], favours
a central role for coactivators in ERα degradation. A
possible role of the CSN in SRC3/AIB1 phosphorylation
and degradation should be investigated.
Figure 1 presents a model summarizing the different steps
that may be involved in estradiol-induced ERα
degradation and the possible links with transcription
activation. ERα-hormone complex interacts with a
coactivator (SRC3/AIB1 in breast cancer cells) and with
CSN5/Jab1. ERα and/or SRC3/AIB1 are phosphorylated
by a curcumin-sensitive kinase, possibly associated with
the CSN, leading to the binding of ERα to promoters of
estrogen regulated genes. Curcumin prevents such
binding either because ERα or SRC3/AIB1
phosphorylation is required for DNA binding, or because
phosphorylation is required for a stable interaction
between ERα and SRC3/AIB1. Upon transcription
initiation, the promoter is cleared. Exchange factors such
as TBL1 or TBLR1 should facilitate recruitment of
coactivators by ERα and of ubiquitin ligase factors at the
promoter. ERα and/or SRC3/AIB1 may be tagged for
degradation as a result of a post-translational modification
and/or a polyubiquitination.The complex containing ERα
and SRC3/AIB1 is then exported to the cytoplasm.The
CSN may promote export of ERα which lacks a nuclear
export signal. Leptomycin B inhibits ERα degradation and
increases hormone dependent transcription, suggesting
that the modifications (putative tagging and/or
polyubiquitination) can be reversed and the complex
recycled.The CSN could be involved at that step through
the recruitment of a deubiquitinating enzyme. In the
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cytoplasm, the ERα-hormone complex is degraded by
the proteasome.
Conclusion
Controversial results regarding the involvement of ERα
degradation in transcriptional activation have been
published. A first set of results suggests that ERα
degradation is required to sustain transcription [Lonard
et al., 2000; Reid et al., 2003], yet another set concludes
that ERα degradation has no general direct effect on
transcription [Alarid et al., 2003; Callige et al., 2005; Fan
et al., 2003]. It should be noted that the experiments
suggesting that ERα degradation is required to sustain
transcription, used treatment times with proteasome
inhibitors or DRB, for longer than 12 hours [Lonard et al.,
2000; Reid et al., 2003]. Such a long treatment time may
have pleiotropic effects on the cell and affect multiple
components of the transcription machinery. In contrast,
the experiments suggesting that ERα degradation has
no influence on transcription, used much shorter treatment
times (less than 3 hours), minimizing general effects of
the inhibitors used. ERα degradation seems rather to be
the consequence of transcription initiation, as shown by
the inhibitory effect of curcumin, rather than transcription
per se, since DRB that blocks transcription does not
prevent hormone-dependent ERα degradation [Alarid et
al., 2003; Callige et al., 2005]. In addition, the nature of
the transcription factors recruited, along with ERα, as
well as the architecture of each promoter seem to be
important, suggesting that the effect of proteasome
inhibitors on transcription results from the degradation of
co-regulators, rather than from that of ERα [Callige et al.,
2005; Fan et al., 2003].
Whatever the role ERα degradation plays at the molecular
level of transcription activation, ligand induced ERα
degradation may be of importance at the physiological
level. Estradiol forms a stable complex with ERα.This
hormone-receptor complex should sustain transcription
for extended periods of time. Degradation of the
ERα-hormone complex at each round of transcription
could be a way for the cell to fine tune transcription
activation in response to rapid changes in hormone
concentration.
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